These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36288186)

  • 1. Prospective Case Series of Clinical Signs and Adrenocorticotrophin (ACTH) Concentrations in Seven Horses Transitioning to Pituitary Pars Intermedia Dysfunction (PPID).
    Kirkwood NC; Hughes KJ; Stewart AJ
    Vet Sci; 2022 Oct; 9(10):. PubMed ID: 36288186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction.
    Menzies-Gow NJ; Banse HE; Duff A; Hart N; Ireland JL; Knowles EJ; McFarlane D; Rendle D
    Equine Vet J; 2024 Mar; 56(2):220-242. PubMed ID: 37795557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of seasonal influences on adrenocorticotropic hormone response to the thyrotropin-releasing hormone stimulation test and its accuracy for diagnosis of pituitary pars intermedia dysfunction.
    Adams AA; Siard-Altman MH; Reedy SE; Barker D; Elzinga S; Sanz MG; Urschel K; Ireland JL
    Vet J; 2023; 300-302():106035. PubMed ID: 37802466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pituitary Pars Intermedia Dysfunction (PPID) in Horses.
    Kirkwood NC; Hughes KJ; Stewart AJ
    Vet Sci; 2022 Oct; 9(10):. PubMed ID: 36288169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia.
    Beech J; Boston R; Lindborg S; Russell GE
    J Am Vet Med Assoc; 2007 Aug; 231(3):417-26. PubMed ID: 17669045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of basal plasma α-melanocyte-stimulating hormone and adrenocorticotrophic hormone concentrations for the diagnosis of pituitary pars intermedia dysfunction from a population of aged horses.
    Mc Gowan TW; Pinchbeck GP; Mc Gowan CM
    Equine Vet J; 2013 Jan; 45(1):66-73. PubMed ID: 22563728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-melanocyte stimulating hormone release in response to thyrotropin releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants.
    McFarlane D; Beech J; Cribb A
    Domest Anim Endocrinol; 2006 May; 30(4):276-88. PubMed ID: 16115743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of blue light therapy on plasma adrenocorticotropic hormone (ACTH) and hypertrichosis in horses with pituitary pars intermedia dysfunction.
    Miller AB; Murphy BA; Adams AA
    Domest Anim Endocrinol; 2022 Jan; 78():106651. PubMed ID: 34656964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seasonal changes in plasma adrenocorticotropic hormone and α-melanocyte-stimulating hormone in response to thyrotropin-releasing hormone in normal, aged horses.
    Funk RA; Stewart AJ; Wooldridge AA; Kwessi E; Kemppainen RJ; Behrend EN; Zhong Q; Johnson AK
    J Vet Intern Med; 2011; 25(3):579-85. PubMed ID: 21457320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.
    Miller AB; Loynachan AT; Bush HM; Hart KA; Barker VD; Campana-Emard AG; Grubbs ST; Adams AA
    Domest Anim Endocrinol; 2021 Jan; 74():106531. PubMed ID: 32942194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of imprecise sampling time for 10- and 30-min thyrotropin-releasing hormone stimulation tests in horses.
    Vorster DM; Wang W; Kemp KL; Bamford NJ; Bertin FR
    Equine Vet J; 2024 Mar; 56(2):291-298. PubMed ID: 37649416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of cortisol and ACTH responses after administration of thyrotropin releasing hormone in normal horses and those with pituitary pars intermedia dysfunction.
    Beech J; Boston R; Lindborg S
    J Vet Intern Med; 2011; 25(6):1431-8. PubMed ID: 22092639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-Term Effects of Temperature and Thyrotropin-Releasing Hormone Stimulation on Adrenocorticotropin Stability in Horses.
    Hinrichsen SL; Yuen KY; Dryburgh EL; Bertin FR; Stewart AJ
    Animals (Basel); 2022 Jan; 12(3):. PubMed ID: 35158648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of freeze-thaw cycles on determination of immunoreactive plasma adrenocorticotrophic hormone concentrations in horses.
    Hu K; Stewart AJ; Yuen KY; Hinrichsen S; Dryburgh EL; Bertin FR
    J Vet Intern Med; 2020 May; 34(3):1350-1356. PubMed ID: 32255541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses.
    McGowan TW; Pinchbeck GP; McGowan CM
    Equine Vet J; 2013 Jan; 45(1):74-9. PubMed ID: 22594955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeatability of a thyrotropin-releasing hormone stimulation test for diagnosis of pituitary pars intermedia dysfunction in mature horses.
    Kam YN; McKenzie K; Coyle M; Bertin FR
    J Vet Intern Med; 2021 Nov; 35(6):2885-2890. PubMed ID: 34642962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of dynamic testing for pituitary pars intermedia dysfunction diagnosis in donkeys.
    Mejia-Pereira S; Perez-Ecija A; Buchanan BR; Toribio RE; Mendoza FJ
    Equine Vet J; 2019 Jul; 51(4):481-488. PubMed ID: 30362589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of pergolide mesylate on adrenocorticotrophic hormone responses to exogenous thyrotropin releasing hormone in horses.
    Durham AE
    Vet J; 2022 Jul; 285():105831. PubMed ID: 35477010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between insulin dysregulation and adrenocorticotropic hormone in aged horses and ponies with no clinical signs of pituitary pars intermedia dysfunction.
    Li FI; Spence RJ; de Laat MA; Harris PA; Sonntag J; Menzies-Gow NJ; Durham AE; Bailey SR; Sillence MN
    Equine Vet J; 2023 Nov; 55(6):1003-1011. PubMed ID: 36641787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circannual variation in plasma adrenocorticotropic hormone concentrations in the UK in normal horses and ponies, and those with pituitary pars intermedia dysfunction.
    Copas VE; Durham AE
    Equine Vet J; 2012 Jul; 44(4):440-3. PubMed ID: 21848531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.